Holen Sie sich die Stockscreener-App
0.6503
2.81%
0.0178
Handel nachbörslich:
.65
-0.0003
-0.05%
Schlusskurs vom Vortag:
$0.6325
Offen:
$0.6351
24-Stunden-Volumen:
38,365
Relative Volume:
0.31
Marktkapitalisierung:
$8.05M
Einnahmen:
$123.30K
Nettoeinkommen (Verlust:
$-11.95M
KGV:
-0.4217
EPS:
-1.5421
Netto-Cashflow:
$-12.57M
1W Leistung:
+4.89%
1M Leistung:
-15.53%
6M Leistung:
-5.75%
1J Leistung:
-60.59%
1-Tages-Spanne:
$0.6005
$0.67
1-Wochen-Bereich:
$0.5901
$0.67
52-Wochen-Spanne:
$0.548
$1.7932
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.6503 | 7.74M | 123.30K | -11.95M | -12.57M | -1.5421 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aprea Therapeutics Inc (APRE) Institutional Confidence - TradingKey
APRE|Aprea Therapeutics Inc|Price:0.620|Chg%:-0.012 - TradingKey
Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
APRE|Aprea Therapeutics Inc|Price:0.632|Chg%:+0.004 - TradingKey
Aprea Therapeutics Inc (APRE) Cash Flow - TradingKey
Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid - Stock Titan
Aprea Therapeutics (APRE) Edges Higher with Modest Gains Amid Tight Trading RangeMedian Line - dars.gov.et
Aprea Therapeutics(APRE) Stock Options Chain | Quotes & News - Moomoo
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
APRE Forecast — Price Target — Prediction for 2027 - TradingView
Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) - TradingView
Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics - BioPharm International
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aprea Shareholders Approve Directors, Reverse Split Flexibility - The Globe and Mail
Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting - Minichart
Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aprea Therapeutics shareholders approve director elections and reverse stock split - Investing.com Nigeria
Aprea Therapeutics shareholders approve director elections and reverse stock split By Investing.com - Investing.com South Africa
APRE: All agenda items, including director elections and reverse stock split, were approved - TradingView
Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5 - Moomoo
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study - MyChesCo
APRE Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Ongoing Clinical DevelopmentManagement Guidance Update - newsline.com
APRE Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesSpecial Dividend Alert - newsline.com
APRE Q1 2026 Earnings: EPS Surpasses Estimates Amid Pre-Revenue StageEarnings Season Review - DonanımHaber
Aprea Expands Cancer Trial After Early Tumor Responses - MyChesCo
ASCO 2026: Drugmakers go ‘WEE1’ for early data - BioWorld News
Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers - BriefGlance
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2 - Moomoo
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - The Manila Times
Cancer trial drug APR-1051 posts partial responses at ASCO 2026 - Stock Titan
Aprea Therapeutics (APRE) Slides 5.86% as Stock Tests Key Support at $0.80Volatility Skew - dars.gov.et
APREAprea Therapeutics Inc Stock Price and Quote - Finviz
Aprea Therapeutics (APRE) Slips 4% as Stock Nears Critical $0.85 Support LevelValue Area High - DonanımHaber
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - The Legal Advocate
Aprea Therapeutics (APRE) Edges Higher Amid Low Volume TradingATR Stop - The Legal Advocate
Aprea Therapeutics (APRE) Gains 2.78% as Shares Approach Key Resistance at $0.99Day Trade Opportunities - dars.gov.et
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aprea Therapeutics Inc-Aktie (APRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Jan 30 '26 |
Buy |
0.89 |
5,700 |
5,073 |
33,433 |
| Duey Marc | Director |
Dec 10 '25 |
Buy |
1.17 |
21,459 |
25,000 |
256,155 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):